In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Sinil Pharmaceutical has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
KOSDAQ:A012790 - Analysts future estimates and past financials data (KRW Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
82,183
6,951
4,818
9,449
N/A
12/31/2025
80,564
7,531
7,676
11,589
N/A
9/30/2025
80,972
11,311
7,794
13,267
N/A
6/30/2025
80,978
11,475
7,434
15,261
N/A
3/31/2025
85,921
12,654
10,671
19,082
N/A
12/31/2024
89,440
14,301
12,232
22,689
N/A
9/30/2024
91,699
15,066
22,352
26,372
N/A
6/30/2024
96,516
15,763
16,003
25,797
N/A
3/31/2024
90,064
13,505
7,818
20,267
N/A
12/31/2023
89,135
13,641
1,494
15,154
N/A
9/30/2023
86,210
12,624
-10,007
11,359
N/A
6/30/2023
81,163
11,613
-5,583
10,633
N/A
3/31/2023
83,914
13,444
-2,343
11,173
N/A
12/31/2022
80,007
12,157
3,309
13,688
N/A
9/30/2022
75,971
11,067
5,766
13,015
N/A
6/30/2022
72,082
10,343
8,690
14,181
N/A
3/31/2022
66,435
8,229
9,447
12,494
N/A
12/31/2021
61,754
6,679
7,534
11,163
N/A
9/30/2021
60,177
5,201
6,733
11,856
N/A
6/30/2021
59,435
5,407
0
7,464
N/A
3/31/2021
59,323
6,494
1,404
10,884
N/A
12/31/2020
61,438
7,544
2,159
11,062
N/A
9/30/2020
63,736
8,359
1,752
11,289
N/A
6/30/2020
63,613
8,072
6,883
14,826
N/A
3/31/2020
63,547
8,017
6,103
14,604
N/A
12/31/2019
60,648
7,257
N/A
12,306
N/A
9/30/2019
57,397
7,115
N/A
11,872
N/A
6/30/2019
54,252
5,497
N/A
10,138
N/A
3/31/2019
53,241
4,767
N/A
6,987
N/A
12/31/2018
53,277
5,714
N/A
9,194
N/A
9/30/2018
52,442
6,385
N/A
2,244
N/A
6/30/2018
52,867
7,888
N/A
5,287
N/A
3/31/2018
51,369
8,293
N/A
10,089
N/A
12/31/2017
50,942
8,198
N/A
8,674
N/A
9/30/2017
50,545
7,731
N/A
20,427
N/A
6/30/2017
49,387
8,376
N/A
15,158
N/A
3/31/2017
49,158
8,840
N/A
10,757
N/A
12/31/2016
50,212
9,360
N/A
12,094
N/A
9/30/2016
49,134
9,432
N/A
5,350
N/A
6/30/2016
48,151
9,352
N/A
8,080
N/A
3/31/2016
46,964
9,117
N/A
7,855
N/A
12/31/2015
44,703
8,764
N/A
9,564
N/A
9/30/2015
45,240
9,405
N/A
12,112
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A012790's forecast earnings growth is above the savings rate (3.1%).
Earnings vs Market: Insufficient data to determine if A012790's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A012790's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A012790's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A012790's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A012790's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/15 22:47
End of Day Share Price
2026/07/15 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinil Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.